The 23 references in paper E. Kosolapov G., F. Kochenkov S., N. Pogudina L., D. Blinov V., Е. Косолапов Г., Ф. Коченков С., Н. Погудина Л., Д. Блинов В. (2017) “Клинико-экономический анализ применения комбинированного препарата вилантерол + умеклидиния бромид для терапии хронической обструктивной болезни легких тяжелого и крайне тяжелого течения по сравнению с монотерапией препаратом тиотропия бромид // COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD” / spz:neicon:pharmacoeconomics:y:2017:i:2:p:31-40

1
Ovcharenko S. I. Lechebnoe Delo. 2004; 2: 24-30.
(check this in PDF content)
2
Gershon A. S. et al. Forecasting Health Services Use In Individuals With Chronic Obstructive Pulmonary Disease (COPD): A Time-Series Analysis //C96. Global Perspectives on COPD Burden and Care Delivery. American Thoracic Society. 2016; A6159-A6159.
(check this in PDF content)
3
Mannino D. M. et al. Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013. International Journal of COPD. 2014; 9: 597-611.
(check this in PDF content)
4
Crighton E. J. et al. A spatial analysis of COPD prevalence, incidence, mortality and health service use in Ontario. Health reports. 2015; 26 (3): 10.
(check this in PDF content)
5
Evans J. et al. Estimating the prevalence of COPD in Canada: Reported diagnosis versus measured airflow obstruction. Health reports. 2014; 25 (3): 3.
(check this in PDF content)
6
Gaigol’nik T. V., Demko I. V., Bochanova E. N., Kraposhina A. Yu., Gordeeva N. V., Solov’eva I. A. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2016; 2: 49-59. DOI: 10.17749/2070-4909.2016.9.2.049-059.
(check this in PDF content)
7
Doklad VOZ. Khronicheskaya obstruktivnaya bolezn’ legkikh (KhOBL): Informatsionnyi byulleten’ No315, 2015. URL: http://www. who.int/mediacentre/factsheets/fs315/ru/. Accessed: 28.12.2016.
(check this in PDF content)
8
Vidyakina E. E., Mal’chikova S. V. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2016; 2: 45-48. DOI: 10.17749/20704909.2016.9.2.045-048.
(check this in PDF content)
9
Chuchalin A. G. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of Chronic Obstructive Pulmonary Disease. 2014; 9: 963-974.
(check this in PDF content)
10
Aleksandrova G. A., Polikarpov A. V., Golubev N. A. et al. The incidence of the entire population of Russia in 2015. Statistical materials. Part I [Zabolevaemost’ vsego naseleniya Rossii v 2015 godu. Statisticheskie materialy. Chast’ I (in Russian)]. Moscow. 2016; 139 s.
(check this in PDF content)
11
Aleksandrova G. A., Polikarpov A. V., Golubev N. A. s soavt. The incidence of the entire population of Russia in 2015. Statistical materials. Part II [Zabolevaemost’ vsego naseleniya Rossii v 2015 godu. Statisticheskie materialy. Chast’ II (in Russian)]. Moscow. 2016; 141 s.
(check this in PDF content)
12
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. URL: http://goldcopd.org. Accessed: 17.03.2017.
(check this in PDF content)
13
Omel’yanovskii V. V., Avksent’eva M. V., Sura M. V., Gerasimova K. V., Dzanaeva A. V. Methodical recommendations for conducting a comparative clinical and economic evaluation of a medicinal product [Metodicheskie rekomendatsii po provedeniyu sravnitel’noi kliniko-ekonomicheskoi otsenki lekarstvennogo preparata (in Russian)]. Moscow. 2016; 20 s.
(check this in PDF content)
14
Omel’yanovskii V. V., Avksent’eva M. V., Sura M. V., Khachatryan G. R., Fedyaeva V. K. Methodical recommendations for the evaluation of the comparative clinical efficacy and safety of the medicinal product [Metodicheskie rekomendatsii po otsenke sravnitel’noi klinicheskoi effektivnosti i bezopasnosti lekarstvennogo preparata (in Russian)]. Moscow. 2016; 58 s.
(check this in PDF content)
15
Omel’yanovskii V. V., Avksent’eva M. V., Sura M. V., Gerasimova K. V., Dzanaeva A. V. Methodical recommendations for assessing the impact on the budget in the framework of the program of state guarantees for free provision of medical care to citizens [Metodicheskie rekomendatsii po otsenke vliyaniya na byudzhet v ramkakh realizatsii programmy gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi (in Russian)]. Moscow. 2016; 28 s.
(check this in PDF content)
16
Starkie H. J., Briggs A. H., Chambers M. G., Jones P. Predicting EQ-5D values using the SGRQ. Value Health. 2011; 14 (2): 354-60.
(check this in PDF content)
17
Maleki-Yazdi M. R., Kaelin T., Richard N. et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014 Dec; 108 (12): 1752-60.
(check this in PDF content)
18
Anoro Ellipta. Instructions for medical use. State Drug Register [Instruktsiya po meditsinskomu primeneniyu. Gosudarstvennyi reestr Lekarstvennykh Sredstv (in Russian)]. URL: www.grls.rosminzdrav.ru. Accessed: 15.12.2016.
(check this in PDF content)
19
Spiriva Respimat. Instructions for medical use. State Drug Register [Instruktsiya po meditsinskomu primeneniyu. Gosudarstvennyi reestr Lekarstvennykh Sredstv (in Russian)]. URL: www.grls. rosminzdrav.ru. Accessed: 15.12.2016.
(check this in PDF content)
20
Global strategy for diagnosis, treatment and prevention of chronic obstructive pulmonary disease (revision 2014) / Trans. With English. Ed. A. S. Belevsky [Global’naya strategiya diagnostiki, lecheniya i profilaktiki khronicheskoi obstruktivnoi bolezni legkikh (peresmotr 2014 g.) / Per. s angl. pod red. A. S. Belevskogo (in Russian)]. Moscow. 2014; 92 s.
(check this in PDF content)
21
Chronic obstructive pulmonary disease. Clinical recommendations [Khronicheskaya obstruktivnaya bolezn’ legkikh. Klinicheskie rekomendatsii (in Russian)]. Moscow. 2016; 69 s.
(check this in PDF content)
22
Makarova E. V., Shumilova S. V., Vakhlamov V. A., Kasatova E. S., Menkov N. V., Lukovnikova N. B., Varvarina G. N., Tyurikova L. V., Karaulov A. V., Novikov V. V. Effect of noninvasive ventilation on functional and immune parameters in patients with severe exacerbation of chronic obstructive pulmonary disease. [Vliyanie neinvazivnoj ventilyacii legkih na funkcional’nye i immunnye pokazateli u bol’nyh s tyazhelym obostreniem hronicheskoj obstruktivnoj bolezni legkih]. Klinicheskaya Medicina. 2017; 95 (4): 344-349 (in Russian).
(check this in PDF content)
23
Makarova E. V., Varvarina G. N., Menkov N. V., Tsapaeva M. Yu., Lazareva E. S., Kazatskaya Zh. A., Novikov V. V., Karaulov A. V. Nebulized budesonide in the treatment of exacerbations of chronic obstructive pulmonary disease: efficacy, safety and effect on the content of soluble differentiation molecules in serum. [Nebulizirovannyj
(check this in PDF content)